Luye Pharma seeks $300m for drugs acquisition
China’s drug developer Luye Pharma Group has launched a $300m loan into general, to back the acquisition of two antipsychotic medical products.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: